Tricares SAS raised $47 million in a first closing of its series C financing to fund further development of Topaz, its minimally invasive treatment for tricuspid regurgitation. The completion of the series C financing round is expected later in 2022.
Immuno-oncology company Imugene Ltd. announced an AU$80 million (US$53.9 million) capital raise that will allow the company to add additional studies within its immuno-oncology pipeline as well as pursue potential licensing opportunities. The funds raised will allow the company to interrogate its pipeline further in other indications or combinations, Imugene CEO Leslie Chong told BioWorld. “There’s a lot we could do with our current pipeline, and now our cashflow is greatly extended.”
Biopharmas raising money in public or private financings, including: Akero, Allakos, Ideaya, Immunoscape, Rhythm, Therapeutic Solutions, Third Harmonic and Virios.
Galvanize Therapeutics Inc. scooped up $100 million in a series B funding round aimed at advancing its pulsed electric field (PEF) energy platform. Completion of the financing coincided with the merger of Galvanize with two other med-tech startups built around the same core intellectual property portfolio: Gala Therapeutics Inc. and Galaxy Medical Inc.
RSS
